Molnupiravir vs nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy: Jon Salmanton-Garcia, ECCMID 2023.

Molnupiravir is an oral antiviral medication that has shown to be effective in treating COVID-19. Nirmatrelvir/ritonavir is a combination of two drugs that have been granted emergency use authorization for the treatment of COVID-19.

Dr Jon Salmanton-Garcia (University of Cologne and University Hospital Cologne, Cologne, Germany) discusses an analysis on the effectiveness of molnupiravir compared to nirmatrelvir/ritonavir in a haematological malignancy patient cohort at high-risk of severe COVID-19.

Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch and Victoria Jones.

Filmed in coverage of the 33rd European Congress of Clinical Microbiology & Infectious Diseases.

свернуть